

Resource Summary Report

Generated by [NIF](#) on Aug 29, 2026

Hs 578T

RRID:CVCL_0332

Type: Cell Line

Proper Citation

RRID:CVCL_0332

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0332

Proper Citation: RRID:CVCL_0332

Description: Cell line Hs 578T is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Invasive breast carcinoma of no special type

Defining Citation: [PMID:283258](#), [PMID:761205](#), [PMID:864756](#), [PMID:1961733](#), [PMID:3335022](#), [PMID:7902062](#), [PMID:9331090](#), [PMID:10700174](#), [PMID:10969801](#), [PMID:15153330](#), [PMID:15677628](#), [PMID:15748285](#), [PMID:16142302](#), [PMID:16397213](#), [PMID:16541312](#), [PMID:16959974](#), [PMID:17088437](#), [PMID:17157791](#), [PMID:17932254](#), [PMID:18277095](#), [PMID:18386134](#), [PMID:18516279](#), [PMID:19372543](#), [PMID:19582160](#), [PMID:19593635](#), [PMID:20070913](#), [PMID:20164919](#), [PMID:21778573](#), [PMID:22068913](#), [PMID:22347499](#), [PMID:22384151](#), [PMID:22460905](#), [PMID:22585861](#), [PMID:22628656](#), [PMID:23151021](#), [PMID:23601657](#), [PMID:23856246](#), [PMID:23933261](#), [PMID:24009699](#), [PMID:24094812](#), [PMID:24162158](#), [PMID:24176112](#), [PMID:24279929](#), [PMID:24670534](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25892236](#), [PMID:25960936](#), [PMID:26589293](#), [PMID:27377824](#), [PMID:27397505](#), [PMID:27807467](#), [PMID:28196595](#), [PMID:28287265](#), [PMID:28889351](#), [PMID:29671673](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31068700](#), [PMID:31733513](#), [PMID:31978347](#), [PMID:35839778](#), [PMID:38861359](#)

Comments: Population: Caucasian., Part of: NCI-60 cancer cell line panel., Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982)., Part of: MD Anderson Cell Lines Project., Part of: KuDOS 95 cell line panel., Part of: JWGray breast cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Group: Triple negative breast cancer (TNBC) cell line.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: Hs 578T

Synonyms: HS 578T, Hs-578T, HS-578T, Hs_578t, Hs-578-T, HS-578-T, Hs 578.T, HS578T, Hs578T, Hs578t, HS0578T, 578T, HS578, Hs578, Homo sapiens No. 578, tumor cells

Cross References: BTO:BTO_0003885, CLO:CLO_0004009, EFO:EFO_0001192, MCCL:MCC:0000228, CLDB:cl1716, CLDB:cl1717, CLDB:cl5023, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ArrayExpress:E-TABM-157, ArrayExpress:E-TABM-244, ATCC:CRL-7849, ATCC:HTB-126, BCRC:60120, BioGRID_ORCS_Cell_line:654, BioSample:SAMN03473213, BioSample:SAMN10987893, cancercellines:CVCL_0332, CCRID:1101HUM-PUMC000670, CCRID:3101HUMTCHu127, CCRID:4201HUM-CCTCC00252, CCTCC:GDC0252, Cell_Model_Passport:SIDM00135, ChEMBL-Cells:ChEMBL3307672, ChEMBL-Targets:ChEMBL614645, CLS:305089, Cosmic:871142, Cosmic:875877, Cosmic:897418, Cosmic:904372, Cosmic:905957, Cosmic:921973, Cosmic:934524, Cosmic:974234, Cosmic:979715, Cosmic:997928, Cosmic:1010929, Cosmic:1017164, Cosmic:1018473, Cosmic:1027051, Cosmic:1044232, Cosmic:1046945, Cosmic:1047714, Cosmic:1092606, Cosmic:1136373, Cosmic:1175831, Cosmic:1176633, Cosmic:1218873, Cosmic:1235086, Cosmic:1287921, Cosmic:1289390, Cosmic:1305385, Cosmic:1312371, Cosmic:1430343, Cosmic:1473054, Cosmic:1518105, Cosmic:1603214, Cosmic:1609463, Cosmic:1998448, Cosmic:2009515, Cosmic:2164996, Cosmic:2301525, Cosmic:2560243, Cosmic:2668302, Cosmic-CLP:905957, DepMap:ACH-000148, DSMZ:ACC-781, DSMZCellDive:ACC-781, ECACC:86082104, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:905957, GEO:GSM2113, GEO:GSM50182, GEO:GSM50246, GEO:GSM217581, GEO:GSM219968, GEO:GSM344346, GEO:GSM344396, GEO:GSM421868, GEO:GSM750776, GEO:GSM783962, GEO:GSM799319, GEO:GSM799382, GEO:GSM839032, GEO:GSM844563, GEO:GSM844564, GEO:GSM844565, GEO:GSM846359, GEO:GSM847392, GEO:GSM847488, GEO:GSM887098, GEO:GSM888169, GEO:GSM1008903, GEO:GSM1053700, GEO:GSM1153388, GEO:GSM1172877, GEO:GSM1181262, GEO:GSM1181319, GEO:GSM1214564, GEO:GSM1238131, GEO:GSM1374549, GEO:GSM1374550, GEO:GSM1669895, GEO:GSM1833625, GEO:GSM2124656, IARC_TP53:579, IBRC:C10150, ICLC:HTL00007, KCB:KCB 2012025YJ, KCLB:30126, LiGeA:CCLE_743, LINCS_HMS:50238, LINCS_LDP:LCL-1315, Lonza:1444, NCI-DTP:HS 578T, Pharmacodb:Hs578T_614_2019, PRIDE:PXD003539, PRIDE:PXD005292, PRIDE:PXD005942, PRIDE:PXD005946, PRIDE:PXD008222, PRIDE:PXD030304, Progenetix:CVCL_0332, PubChem_Cell_line:CVCL_0332, SKY/M-FISH/CGH:2663, SLKBase:3558, Wikidata:Q54895774

ID: CVCL_0332

Record Creation Time: 20220427T220606+0000

Record Last Update: 20260815T234232+0000

Ratings and Alerts

No rating or validation information has been found for Hs 578T.

Warning: Discontinued: ATCC; CRL-7849

Population: Caucasian., Part of: NCI-60 cancer cell line panel., Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982)., Part of: MD Anderson Cell Lines Project., Part of: KuDOS 95 cell line panel., Part of: JWGray breast cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Group: Triple negative breast cancer (TNBC) cell line.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 1355 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Xu Y, et al. (2026) Comprehensive single-cell metabolic profiling identifies targets to sensitize triple-negative breast cancer to chemo-immunotherapy. *Cell reports. Medicine*, 7(3), 102659.

Ohashi T, et al. (2026) ZSTK3744, a Novel Aryl Hydrocarbon Receptor Agonist, Exhibits Efficacy against Chemotherapy-Resistant Triple-Negative Breast Cancer. *Cancer research communications*, 6(2), 421.

Yang T, et al. (2026) Covalent Inhibition of SHMT2 by Gambogic Acid Induces Ferroptosis Through Mitochondrial Collapse in Triple-Negative Breast Cancer. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, 13(42), e20252.

Hu X, et al. (2026) Immune gene diversity and STING1 variants in shaping cancer immunity across different genetic ancestry populations. *Cell reports*, 45(2), 116882.

Ott LF, et al. (2026) Fast enrichment and detection of circulating tumor cells from large volumes of whole blood of breast cancer patients utilizing a functionalized bioaffinity CTC filtration membrane. *International journal of cancer*, 158(6), 1713.

Ortega-Álvarez D, et al. (2026) Discovery and Evaluation of Biomarkers for Triple-Negative Breast Cancer Subtypes Uncovers Patient Stratification and Targeted Therapeutic Strategies. *Cancer research*, 86(10), 2360.

Luan H, et al. (2026) Orai1 is required for Ca²⁺-dependent plasma membrane repair and mechanoadaptation. *bioRxiv : the preprint server for biology*.

Ranganathan S, et al. (2026) Gasdermin D Cleavage and Cytokine Release, Indicative of Pyroptotic Cell Death, Induced by Ophiobolin A in Breast Cancer Cell Lines. *International journal of molecular sciences*, 27(2).

Sun Y, et al. (2026) CircNSD2 promotes metastasis and immune escape by increasing the USP10/SRSF6-mediated alternative splicing of TPM1 in TNBC. *Molecular cancer*, 25(1).

Zhao W, et al. (2026) Arginine methylation-dependent stabilization of SUV39H1 promotes breast cancer growth. *Oncogene*, 45(14), 1220.

Wang Z, et al. (2026) RAD51 succinylation regulates homologous recombination and contributes to the chemosensitivity in cancer. *Molecular cell*, 86(4), 585.

Liu J, et al. (2026) Targeting the noncanonical function of metabolic enzyme PHGDH in driving PD-L1 expression and cancer immune evasion. *Cell reports. Medicine*, 7(4), 102704.

Zhang R, et al. (2026) Targeting a Glutamic Acid in PDE γ with Fluoromethyl-Aryl Electrophiles Impairs K-Ras Signaling. *Journal of medicinal chemistry*.

Fang Y, et al. (2026) NFYC upregulates KLF1 expression and activate LDHA to drive glycolysis and tumor growth in glioblastoma cells. *Frontiers in cell and developmental biology*, 14, 1810731.

Zhao L, et al. (2026) Integrative Genomic Analysis Identifies MAGT1 as a Key Regulator of Proliferation and Poor Prognosis in Breast Cancer. *Human mutation*, 2026, 8673018.

Galifi CA, et al. (2026) Insulin-like growth factor 1 receptor regulates breast cancer cell adhesion through beta-1 integrin. *Frontiers in endocrinology*, 17, 1701560.

Matsuura K, et al. (2026) Distinct metabolic dependency on BCAA defines cancer stemness and malignancy in human triple-negative breast cancer. *Cell reports*, 45(7), 117630.

Lerévérénd C, et al. (2025) Enhanced expression of galectin-9 in triple negative breast cancer cells following radiotherapy: Implications for targeted therapy. *International journal of cancer*, 156(1), 229.

Williams J, et al. (2025) Tumor cell-adipocyte gap junctions activate lipolysis and contribute to breast tumorigenesis. *Nature communications*, 16(1), 7438.

Pelzer N, et al. (2025) PHF19 drives the formation of PRC2 clusters to enhance motility in TNBC cells. *Cell reports*, 44(10), 116391.